Type 1 DiabetesSupplementsNutrition and dietHealthy volunteersDrugEarly Phase 1
What this study is
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
What's being tested
- Resveratrol
Intervention · DRUG
500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
- Placebo
Intervention · OTHER
placebo for 12 weeks
Study details
- Sponsor
- Augusta University
- Conditions
- Type 1 Diabetes
- Enrolling
- 24 people
- Starts
- 2020-10-14
- Est. completion
- 2027-07-01
- Design
- Double-blind, randomized, parallel groups, Early Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Men and premenopausal women
- All races
- Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
You can't join if
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Uncontrolled diabetes (HbA1C >12%)
- Diabetic complications (i.e. neuropathy)
- Uncontrolled hypertension (>140/90 mm Hg on therapy)
- Pregnancy
- Use of vasoactive medications
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openAugusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
Augusta, Georgia, United States
- Ryan Harris, PhD, CEP · Contact706-721-5998ryharris@augusta.edu
- Casey Derella, BS · Contact706-721-5483cderella@augusta.edu
Recruiting
Study team
Sponsor
Augusta University
Study ID 1595933
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.